BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Analysts

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have earned a consensus recommendation of “Moderate Buy” from the twenty-three research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $89.1739.

A number of research firms have recently commented on BMRN. Citigroup raised their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. UBS Group set a $88.00 price target on BioMarin Pharmaceutical in a report on Wednesday, August 26th. Canaccord Genuity Group increased their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Royal Bank Of Canada dropped their price objective on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Finally, Bank of America dropped their price objective on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th.

BioMarin Pharmaceutical Stock Performance

BMRN opened at $65.51 on Friday. The firm has a fifty day moving average price of $63.16 and a 200 day moving average price of $58.45. BioMarin Pharmaceutical has a 1 year low of $49.26 and a 1 year high of $70.98. The stock has a market cap of $12.68 billion, a P/E ratio of 177.05, a P/E/G ratio of 0.46 and a beta of 0.24. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. During the same quarter last year, the business earned $1.44 earnings per share. The firm’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts anticipate that BioMarin Pharmaceutical will post 4.1 earnings per share for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in BMRN. Sequoia Financial Advisors LLC lifted its holdings in BioMarin Pharmaceutical by 70.8% during the second quarter. Sequoia Financial Advisors LLC now owns 12,796 shares of the biotechnology company’s stock valued at $732,000 after purchasing an additional 5,305 shares in the last quarter. NewEdge Advisors LLC grew its position in shares of BioMarin Pharmaceutical by 12.1% in the second quarter. NewEdge Advisors LLC now owns 27,287 shares of the biotechnology company’s stock valued at $1,561,000 after purchasing an additional 2,936 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 187 shares in the last quarter. Corient Private Wealth LP increased its stake in shares of BioMarin Pharmaceutical by 485.0% during the second quarter. Corient Private Wealth LP now owns 35,525 shares of the biotechnology company’s stock worth $2,033,000 after purchasing an additional 29,452 shares in the last quarter. Finally, Amundi raised its position in shares of BioMarin Pharmaceutical by 37.8% during the 2nd quarter. Amundi now owns 259,782 shares of the biotechnology company’s stock worth $14,865,000 after purchasing an additional 71,246 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Positive Phase 3 VOXZOGO data: BioMarin reported that the CANOPY-HCH-3 study in children with hypochondroplasia achieved statistically significant improvements in annualized growth velocity, standing height, height Z-score and arm span. The results were published in NEJM Evidence and presented at the ESPE 2026 meeting, strengthening the case for expanding VOXZOGO’s addressable market. BioMarin Announces Positive Results of Phase 3 VOXZOGO Study
• Positive Sentiment: Regulatory expansion opportunity: BioMarin recently submitted a supplemental New Drug Application to the FDA seeking approval to use VOXZOGO in children with hypochondroplasia. Successful review could broaden the product’s commercial opportunity and support investor sentiment. BioMarin’s VOXZOGO Hits Phase 3 Growth Endpoint
• Neutral Sentiment: Investor conference updates: BioMarin presented at the Citigroup, Cantor Fitzgerald and Wells Fargo healthcare conferences. The transcripts provide additional management commentary on the pipeline and business outlook, but the supplied reports do not identify a new material financial or clinical announcement. Citigroup conference transcript
• Neutral Sentiment: Short-interest report appears unreliable: The report lists short interest at zero shares and a zero-day days-to-cover ratio, offering no meaningful bearish or bullish signal and likely reflecting a data-quality issue.
• Negative Sentiment: Analyst remains cautious: HC Wainwright reaffirmed a “neutral” rating and assigned a $60 price target, below the referenced $65.51 share price. That implies potential downside and signals skepticism about near-term valuation or execution. HC Wainwright analyst rating

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.

BioMarin’s marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates.